Quantcast

Pulmonary Drug Delivery Systems Market (Products - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications - Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 - KOAM TV 7

Pulmonary Drug Delivery Systems Market (Products - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications - Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker



 

 

 

NEW YORK, June 23, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pulmonary Drug Delivery Systems Market (Products - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications - Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

http://www.reportlinker.com/p02042901/Pulmonary-Drug-Delivery-Systems-Market-Products---Metered-Dose-Inhalers-Dry-Powder-Inhalers-and-Nebulizers-Applications---Asthma-COPD-and-Cystic-Fibrosis---Global-Industry-Analysis-Size-Share-Growth-Trends-and-Forecast-2013---2019.html

This report studies the current scenario as well as the future market potential for pulmonary drug delivery systems, globally. The market for pulmonary drug delivery systems has been segmented into three major product types, namely, metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. The market for these systems has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence and technological developments. On the basis of therapeutic application, the market has been segmented into asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019.

Geographically, the market for pulmonary drug delivery systems has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis.

The report also provides a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global pulmonary drug delivery systems market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the global pulmonary drug delivery systems market such as AstraZeneca plc, CareFusion Corporation, GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co., 3M Health Care, Novartis AG, Omron Healthcare, Inc., PARI Respiratory Equipment, Inc., Sunovion Pharmaceuticals Inc., Philips Respironics, Inc., Allied Healthcare Products, Inc., and GF Health Products Inc.


The global pulmonary drug delivery systems market is segmented as follows:

Pulmonary Drug Delivery Systems Market, by Product Type

Metered Dose Inhalers (MDIs)
Dry Powder Inhalers (DPIs)
Nebulizers

Pulmonary Drug Delivery Systems Market, by Application

Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Cystic Fibrosis

Pulmonary Drug Delivery Systems Market, by Geography

North America
Europe
Asia-Pacific
Rest of the World (RoW)


TABLE OF CONTENT

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Increasing patient base affected with respiratory diseases
3.2.2 Advantages associated with pulmonary drug delivery route
3.2.3 Technical advances in pulmonary drug delivery systems as well as drug formulations
3.2.4 Expanding therapeutic applications
3.3 Market Restraints
3.3.1 Patent expiry of drug delivery systems
3.3.2 Regulatory hurdles
3.4 Market Opportunities
3.4.1 Developing nations (BRICS) present immense market potential for pulmonary drug delivery systems
3.4.2 Emphasis on developing breakthrough technology related with DPIs
3.5 Porter's Five Forces Analysis: Global Pulmonary Drug Delivery Systems Market
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Threat of substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Pulmonary Drug Delivery Systems Market, by Geography

Chapter 4 Global Pulmonary Drug Delivery Systems Market Revenue, by Product Type, 2011 - 2019 (USD Million)
4.1 Overview
4.1.1 Global Pulmonary Drug Delivery Systems Market Revenue, by Product Type, 2011 – 2019 (USD Million)
4.1.2 Comparative Analysis: Global Pulmonary Drug Delivery Systems Market Revenue, by Product Type, 2012 & 2019 (Value %)
4.2 Metered Dose Inhalers (MDIs)
4.2.1 Global Metered Dose Inhalers Market Revenue, 2011 – 2019 (USD Million)
4.3 Dry Powder Inhalers (DPIs)
4.3.1 Global Dry Powder Inhalers Market Revenue, 2011 – 2019 (USD Million)
4.4 Nebulizers
4.4.1 Global Nebulizers Market Revenue, 2011 – 2019 (USD Million)

Chapter 5 Global Pulmonary Drug Delivery Systems Market Revenue, by Application, 2011 - 2019 (USD Million)
5.1 Overview
5.1.1 Global Pulmonary Drug Delivery Systems Market Revenue, by Application, 2011 – 2019 (USD Million)
5.1.2 Comparative Analysis: Global Pulmonary Drug Delivery Systems Market Revenue, by Application, 2012 & 2019 (Value %)
5.2 Asthma
5.2.1 Global Pulmonary Drug Delivery Systems in Asthma Market Revenue, 2011 – 2019 (USD Million)
5.3 Chronic Obstructive Pulmonary Disease (COPD)
5.3.1 Global Pulmonary Drug Delivery Systems in COPD Market Revenue, 2011 – 2019 (USD Million)
5.4 Cystic Fibrosis
5.4.1 Global Pulmonary Drug Delivery Systems in Cystic Fibrosis Market Revenue, 2011 – 2019 (USD Million)

Chapter 6 Global Pulmonary Drug Delivery Systems Market Revenue, by Geography, 2011 - 2019 (USD Million)
6.1 Overview
6.1.1 Global Pulmonary Drug Delivery Systems Market Revenue, by Geography, 2011 - 2019 (USD Million)
6.1.2 Comparative Analysis: Global Pulmonary Drug Delivery Systems Market Revenue, by Geography, 2012 & 2019 (Value %)
6.2 North America
6.2.1 North America Pulmonary Drug Delivery Systems Market Revenue, 2011 - 2019 (USD Million)
6.3 Europe
6.3.1 Europe Pulmonary Drug Delivery Systems Market Revenue, 2011 - 2019 (USD Million)
6.4 Asia-Pacific
6.4.1 Asia-Pacific Pulmonary Drug Delivery Systems Market Revenue, 2011 - 2019 (USD Million)
6.5 Rest of the World (RoW)
6.5.1 Rest of the World (RoW) Pulmonary Drug Delivery Systems Market Revenue, 2011 - 2019 (USD Million)


Chapter 7 Competitive Landscape
7.1 Market Share Analysis, by Key Players, 2012 (%)

Chapter 8 Recommendations
8.1 Focus on generic versions of brands that have already lost or are likely to lose patent exclusivity in near future
8.2 Investing in emerging economies
8.3 Emphasis on developing technologically advanced products

Chapter 9 Company Profiles
9.1 3M Health Care
9.1.1 Company Overview
9.1.2 Financial Overview
9.1.3 Product Portfolio
9.1.4 Recent Developments
9.2 Allied Healthcare Products, Inc.
9.2.1 Company Overview
9.2.2 Financial Overview
9.2.3 Product Portfolio
9.2.4 Business Strategies
9.3 AstraZeneca plc
9.3.1 Company Overview
9.3.2 Financial Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies
9.3.5 Recent Developments
9.4 Boehringer Ingelheim
9.4.1 Company Overview
9.4.2 Financial Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies
9.4.5 Recent Developments
9.5 CareFusion Corporation
9.5.1 Company Overview
9.5.2 Financial Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies
9.5.5 Recent Developments
9.6 GF Health Products, Inc.
9.6.1 Company Overview
9.6.2 Product Portfolio
9.6.3 Business Strategies
9.7 GlaxoSmithKline plc
9.7.1 Company Overview
9.7.2 Financial Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies
9.7.5 Recent Developments
9.8 Merck & Co., Inc.
9.8.1 Company Overview
9.8.2 Financial Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies
9.9 Novartis AG
9.9.1 Company Overview
9.9.2 Financial Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies
9.9.5 Recent Developments
9.10 Omron Healthcare, Inc.
9.10.1 Business Overview
9.10.2 Financial Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies
9.10.5 Recent Developments
9.11 PARI Respiratory Equipment, Inc.
9.11.1 Company Overview
9.11.2 Product Portfolio
9.11.3 Business Strategies
9.12 Philips Healthcare
9.12.1 Company Overview
9.12.2 Financial Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies
9.12.5 Recent Developments
9.13 Sunovion Pharmaceuticals Inc.
9.13.1 Company Overview
9.13.2 Financial Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies
9.13.5 Recent Developments


List of Figures

FIG. 1 Pulmonary Drug Delivery Systems: Market Segmentation
FIG. 2 Global Pulmonary Drug Delivery Systems Market, by Product Type, 2012 (USD Million)
FIG. 3 Global Pulmonary Drug Delivery Systems Market, by Application, 2012 (USD Million)
FIG. 4 Porter's Five Force Analysis: Global Pulmonary Drug Delivery Systems Market
FIG. 5 Market Attractiveness Analysis: Global Pulmonary Drug Delivery Systems Market, by Geography (2012)
FIG. 6 Comparative Analysis: Global Pulmonary Drug Delivery Systems Market Revenue, by Product Type, 2012 & 2019 (Value %)
FIG. 7 Global Metered Dose Inhalers Market Revenue, 2011 – 2019 (USD Million)
FIG. 8 Global Dry Powder Inhalers Market Revenue, 2011 – 2019 (USD Million)
FIG. 9 Global Nebulizers Market Revenue, 2011 – 2019 (USD Million)
FIG. 10 Comparative Analysis: Global Pulmonary Drug Delivery Systems Market Revenue, by Application, 2012 & 2019 (Value %)
FIG. 11 Global Pulmonary Drug Delivery Systems in Asthma Market Revenue, 2011 – 2019 (USD Million)
FIG. 12 Global Pulmonary Drug Delivery Systems in COPD Market Revenue, 2011 – 2019 (USD Million)
FIG. 13 Global Pulmonary Drug Delivery Systems in Cystic Fibrosis Market Revenue, 2011 – 2019 (USD Million)
FIG. 14 Comparative Analysis: Global Pulmonary Drug Delivery Systems Market Revenue, by Geography, 2012 & 2019 (Value %)
FIG. 15 North America Pulmonary Drug Delivery Systems Market Revenue, 2011 – 2019 (USD Million)
FIG. 16 Europe Pulmonary Drug Delivery Systems Market Revenue, 2011 – 2019 (USD Million)
FIG. 17 Asia-Pacific Pulmonary Drug Delivery Systems Market Revenue, 2011 – 2019 (USD Million)
FIG. 18 RoW Pulmonary Drug Delivery Systems Market Revenue, 2011 – 2019 (USD Million)
FIG. 19 Pulmonary Drug Delivery Systems: Market Share, by Key Players, 2012 (%)
FIG. 20 Annual Revenue: 3M Health Care, 2010 – 2012 (USD Million)
FIG. 21 Annual Revenue: Allied Healthcare Products, Inc., 2010 – 2012 (USD Million)
FIG. 22 Annual Revenue: AstraZeneca plc, 2010 – 2012 (USD Million)
FIG. 23 Annual Revenue: Boehringer Ingelheim, 2010 – 2012 (USD Million)
FIG. 24 Annual Revenue: CareFusion Corporation, 2010 – 2012 (USD Million)
FIG. 25 Annual Revenue: GlaxoSmithKline plc, 2010 – 2012 (USD Million)
FIG. 26 Annual Revenue: Merck & Co., Inc, 2010 – 2012 (USD Million)
FIG. 27 Annual Revenue: Novartis AG, 2010 – 2012 (USD Million)
FIG. 28 Annual Revenue: Omron Healthcare, Inc., 2010 – 2012 (USD Million)
FIG. 29 Annual Revenue: Philips Healthcare 2010 – 2012 (USD Million)
FIG. 30 Annual Revenue: Sunovion Pharmaceuticals Inc., 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Pulmonary Drug Delivery Systems Market (2012 & 2019)
TABLE 2 Global Pulmonary Drug Delivery Systems Market Revenue, by Product Type, 2011 – 2019 (USD Million)
TABLE 3 Key MDI Products: Manufacturers, Drug Used, Patent Approval and Expiry Information
TABLE 4 Key DPI Products: Manufacturers, Drug Used, Patent Approval and Expiry Information
TABLE 5 Global Pulmonary Drug Delivery Systems Market Revenue, by Application, 2011 – 2019 (USD Million)
TABLE 6 Global Pulmonary Drug Delivery Systems Market Revenue, by Geography, 2011 – 2019 (USD Million)




To order this report: Pulmonary Drug Delivery Systems Market (Products - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications - Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
http://www.reportlinker.com/p02042901/Pulmonary-Drug-Delivery-Systems-Market-Products---Metered-Dose-Inhalers-Dry-Powder-Inhalers-and-Nebulizers-Applications---Asthma-COPD-and-Cystic-Fibrosis---Global-Industry-Analysis-Size-Share-Growth-Trends-and-Forecast-2013---2019.html



__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

KOAM - Licensed to Pittsburg, Kansas
Send tips, ideas and press releases to: tips@koamtv.com
Send newsroom questions or comments to: comments@koamtv.com
Phone: (417) 624-0233 or (620) 231-0400
Web comments or questions: webmaster@koamtv.com
Newsroom Fax: (417) 624-3158

Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and KOAM. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.